Sera Prognostics is revolutionizing pregnancy care with a focus on reducing the burden of preterm birth through innovative diagnostics and solutions.
The company aims to become a global leader in high-value women's health diagnostics by providing pivotal information to improve health outcomes for mothers and babies.
Sera Prognostics' flagship product, the PreTRM® test, is a groundbreaking blood-based predictor of spontaneous preterm birth risk.
PreTRM® Test: A Game-Changer
The PreTRM® test is the only clinically validated predictor of premature birth risk, backed by 8 independent clinical studies.
Financial Strength
With $102.4 million in cash, cash equivalents, and marketable securities as of September 30, 2025, Sera Prognostics is financially well-positioned for growth.
Addressing a Critical Issue
Sera Prognostics is addressing the $25.2 billion economic cost of preterm birth in the US, aiming to improve maternal and neonatal outcomes.
- The US faces a significant premature birth problem, with preterm birth rates on the rise. Sera Prognostics' focus on predictive diagnostics can lead to better outcomes for at-risk pregnancies.
- By providing early detection and intervention through the PreTRM® test, Sera Prognostics is positioned to make a tangible impact in reducing preterm birth rates and improving healthcare economics.
Sera Prognostics' dedication to revolutionizing pregnancy care and reducing preterm birth rates signifies a transformative step in women's health diagnostics. With innovative solutions and a strong financial position, the company is poised to make a meaningful difference in maternal and neonatal outcomes.